Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Acute Lymphoblastic Leukemia
Interventions
DRUG

Cyclophosphamide (CTX)

300 mg/m\^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of

DRUG

Vincristine

2 mg by vein (IV) weekly for 3: Days 1, 8, 15

DRUG

Doxorubicin

50 mg/m\^2 by vein (IV) over 24 hours

DRUG

Decadron

80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18

DRUG

G-CSF

10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours

DRUG

Methotrexate (MTX)

200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1

DRUG

Ara-C

3 gm/m\^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.

DRUG

Pegaspargase

2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Enzon Pharmaceuticals, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER